Literature DB >> 29427500

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.

Maria Buti1,2, Mar Riveiro-Barciela1,2, Rafael Esteban1,2.   

Abstract

Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic hepatitis B; efficacy; entecavir; safety; tenofovir alafenamide; tenofovir disoproxil fumarate; treatment

Mesh：

Substances：

Year:  2018        PMID： 29427500     DOI： 10.1111/liv.13641

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


  11 in total

1.  Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.

Authors:  Jung Woo Shin; Joonho Jeong; Seok Won Jung; Seung Bum Lee; Bo Ryung Park; Min-Ju Kim; Eun Ji Park; Neung Hwa Park
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

2.  Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B.

Authors:  Yusuf Emre Ozdemir; Meryem Sahin Ozdemir; Osman Faruk Bayramlar; Serkan Surme; Sibel Yildiz Kaya; Ridvan Karaali; Ilker Inanc Balkan; Bilgul Mete; Nese Saltoglu; Fehmi Tabak
Journal:  Ir J Med Sci       Date:  2022-06-18       Impact factor: 1.568

3.  Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.

Authors:  Sara Jeong; Hyun Phil Shin; Ha Il Kim
Journal:  Intervirology       Date:  2021-11-03       Impact factor: 2.294

4.  APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.

Authors:  Jia-Horng Kao; Tung-Hung Su; Wen-Juei Jeng; Qin Ning; Tai-Chung Tseng; Yoshiyuki Ueno; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2021-07-23       Impact factor: 6.047

5.  Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).

Authors:  Chun-Jen Liu; Ming-Lung Yu; Ming-Lun Yeh; Chao-Hung Hung; Kuo-Chih Tseng; Hsueh-Chou Lai; Chi-Yi Chen; Hsing-Tao Kuo; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Chun-Yen Lin; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Shui-Yi Tung; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Pei-Chien Tsai; Cheng-Yuan Peng
Journal:  Hepatol Int       Date:  2021-08-07       Impact factor: 6.047

6.  Immunological Efficacy of Tenofovir Disproxil Fumarate-Containing Regimens in Patients With HIV-HBV Coinfection: A Systematic Review and Meta-Analysis.

Authors:  Taiyi Jiang; Bin Su; Ting Song; Zhiqiang Zhu; Wei Xia; Lili Dai; Wen Wang; Tong Zhang; Hao Wu
Journal:  Front Pharmacol       Date:  2019-09-12       Impact factor: 5.810

7.  Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis.

Authors:  Mao-Bing Chen; Hua Wang; Qi-Han Zheng; Wei-Yan Cui; Hua-Lan Xu; Xu-Wen Zheng
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

8.  Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.

Authors:  Sylvia M Brakenhoff; Robert A de Man; André Boonstra; Margo J H van Campenhout; Robert J de Knegt; Florian van Bömmel; Annemiek A van der Eijk; Thomas Berg; Bettina E Hansen; Harry L A Janssen; Milan J Sonneveld
Journal:  Aliment Pharmacol Ther       Date:  2020-11-21       Impact factor: 8.171

9.  Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps.

Authors:  Antoine Jaquet; Guy Muula; Didier K Ekouevi; Gilles Wandeler
Journal:  Curr Epidemiol Rep       Date:  2021-07-31

10.  Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.

Authors:  Hyung Joon Yim; Won Kim; Sang Hoon Ahn; Jin Mo Yang; Jae Young Jang; Yong Oh Kweon; Yong Kyun Cho; Yoon Jun Kim; Gun Young Hong; Dong Joon Kim; Young Kul Jung; Soon Ho Um; Joo Hyun Sohn; Jin Woo Lee; Sung Jae Park; Byung Seok Lee; Ju Hyun Kim; Hong Soo Kim; Seung Kew Yoon; Moon Young Kim; Kwan Sik Lee; Young Suk Lim; Wan Sik Lee; Kwang-Hyub Han
Journal:  Am J Gastroenterol       Date:  2020-08       Impact factor: 12.045
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.